Veracyte (VCYT) 10-Q2022 Q1 Quarterly report

Filed: 3 May 22, 5:57pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acquiree, artificial, Asia, Brazil, Brightplex, Canadian, carryforward, CDRH, climate, coinciding, Colorado, Commissioner, convey, CPRA, downturn, driven, easily, EUA, fact, formally, foster, gave, Geral, heavily, Immunosign, importantly, inflation, kidney, KOL, lab, leave, left, Lei, LGPD, match, MD, MDs, narrower, Nebraska, Oceania, opt, optical, PIPL, population, pose, primer, prolonged, purposefully, raw, reagent, referendum, remanufacture, reprice, residency, reuse, ROU, SCC, sector, sophisticated, TMExplore, turnaround, Ukraine, undetected, unintended, upload, Utah, variation, waiting, Washington, weak, weakened

Removed: acceleration, accounted, acid, adulterated, aforementioned, aid, airway, Alley, allocate, alteration, amending, analyzed, Anderson, arena, aspiration, belief, biased, biochemically, Bonnie, brushing, calculating, castrate, caution, cell, Chair, chemotherapy, chosen, clarifying, classify, cloud, commentary, commented, complicate, conditioned, conflicted, continuing, contradict, cooperate, crucial, cystectomy, cytology, deductible, deducting, Dendreon, dependence, detecting, detection, dialogue, diffuse, digital, DLBCL, document, dossier, downgrade, elimination, enable, enrolled, ERLEADA, examining, extensively, extracted, fewer, finalizing, forma, fusion, gauge, genetically, grace, grant, guide, hallmark, hereof, hiring, importance, improved, inconclusive, inconsistent, informational, insist, intensified, Intermediate, intraperiod, intrinsic, invalidating, invasive, Jane, Janssen, Journal, judicial, largest, legacy, licensee, manager, Marc, medullary, metastatic, misbranded, monotherapy, nasal, needle, neoadjuvant, nmCRPC, noncash, noninvasive, nonrecurring, nonsurgical, option, origin, outright, Paper, partnership, pattern, phased, pivotal, pneumonia, powerful, presence, pro, profiling, progressing, prominence, proposing, prostatectomy, publishing, purporting, radical, radiotherapy, randomized, realization, recurrence, recurrent, reliable, removing, represent, resistant, ribonucleic, rotational, rulemaking, salvage, send, Shield, showing, simple, simplify, Simplifying, size, slide, small, Society, spark, SPARTAN, Stapley, statement, statistical, step, stored, subtype, sued, suggested, surgical, suspected, swab, tailored, tool, transbronchial, treat, treating, tumor, UIP, undergoing, undermine, underwriting, unified, untreated, unvested, vested, visibility, XA

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VCYT transcripts

VCYT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Veracyte, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:

May 3, 2022

/s/ Marc Stapley

Marc Stapley

Chief Executive Officer

(Principal Executive Officer)